CD95 Antigen Mutations in Hematopoietic Malignancies

References

• Lynch D H, Ramsdell F, Alderson M R. Fas and fasL in the homeostatic regulation of immune responses. Imm Today 1995; 16: 569–574
   PubMedGoogle Scholar
• Daniel F T, Krammer P H. Activation induces sensitivity toward APO-1 (CD95)-mediated apoptosis in human B cells. J Immunol 1994; 152: 5624–5632
   PubMed Web of Science ®Google Scholar
• Kobayashi N, Hamamoto Y, Yamamoto N, Ishii A, Yonehara M, Yonehara S. Anti-Fas monoclonal antibody is cytocidal to human immunodeficiency virus-infected cells without augmenting viral replication. Proc Natl Acad Sci USA 1990; 87: 9620–9624
   PubMed Web of Science ®Google Scholar
• Watanabe-Fukunaga R, Brannan C I, Itoh N, Yonehara S, Copeland N G, Jenkins N A, Nagata S. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J Immunol 1992; 148: 1274–1279
   PubMed Web of Science ®Google Scholar
• Falk M H, Trauth B C, Debatin K-M, Klas C, Gregory C D, Rickinson A B, Calendar A, Lenoir G M, Ellwart J W, Krammer P H, Bomkamm G W. Expression of the APO-1 antigen in Burkitt Lymphoma cell lines correlates with a shift towards a lymphoblastoid phenotype. Blood 1992; 79: 3300–3306
   PubMed Web of Science ®Google Scholar
• Itoh N, Nagata S. A novel protein domain required for apoptosis: Mutational analysis of human Fas antigen. J Biol Chem 1993; 268: 10932–10937
   PubMed Web of Science ®Google Scholar
• Kischkel F C, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer P H, Peter M E. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 1995; 14: 5579–5588
   PubMed Web of Science ®Google Scholar
• Kataoka S, Schroter M, Hahne M, Schneider P, Irmler M, Thome M, Froelich C J, Tschopp I. FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irraadiation. J Immunol 1998; 1661(15)3936–3942
   Google Scholar
• Scaffidi C, Schneider P, Krammer P H, Peter M E. The role of c-FLIP in modulation of CD95-induced apoptosis. J Biol Chem 1999; 274(3)1541–1548
   PubMed Web of Science ®Google Scholar
• Yang X, Khosravi-Far R, Chang H Y, Baltimore D. Daxx, a novel Fas-binding protein that activates INK and apoptosis. Cell 1997; 89: 1067–1076
   PubMed Web of Science ®Google Scholar
• Sato T, We S, Kitada S, Reed J C. FAP-1: A protein tyrosine phosphatase that associates with Fas. Science 1995; 268: 411–415
   PubMed Web of Science ®Google Scholar
• Yanagisawa I, Takahashi M, Kanki H, Yano-Yanagisawa H, Tazunoli T, Sawa E, Nishitoba T, Kamishohara M, Kobayashi E, Kataoka S, Sato T. The molecular interaction of Fas and FAP-1: A tripeptide blocker of human Fas interaction with FAP-1 promotes Fas-induced apoptosis. J Biol Chem 1997; 272: 8539–8545
   PubMed Web of Science ®Google Scholar
• Komada Y, Inaba H, Zhou Y-W, Zhang X-L, Tanaka S, Azuma E, Sakurai M. mRNA expression of Fas receptor (CD95)-associated proteins (Fas-associated phosphatase-1/FAP-1, Fas-associating protein with death domain/FADD, and receptor-interacting protein/RIP) in human leukaemia/lymphoma cell lines. Br J Haematology 1997; 99: 325–330
   PubMed Web of Science ®Google Scholar
• Levy-Strumpf N, Kimchi A. Death associated proteins (DAPs): from gene identification to the analysis of their apoptotic and tumor suppressive functions. Oncogene 1998; 17: 3331–3340
   PubMed Web of Science ®Google Scholar
• Takahashi T, Tanaka M, Brannan C I, Jenkins N A, Copeland N G, Suda T, Nagata S. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994; 76: 969–976
   PubMed Web of Science ®Google Scholar
• Watanabe-Fukunaga R, Brannan C I, Copeland N G, Jenkins N A, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356: 314–317
   PubMed Web of Science ®Google Scholar
• Wu J, Zhou T, Zhang J, He J, Gause W C, Mountz J D. Correction of accelerated autoimmune disease by early replacement of the mutated Ipr gene with the normal Fas apoptosis gene in the T cells of transgenic MRL-lpr/lpr mice. Proc Natl Acad Sci USA 1994; 91: 2344–2348
   PubMed Web of Science ®Google Scholar
• Rieux-Laucat F, Le Deist F, Hivroz C, Roberts I AG, Debatin K-M, Fischer A, de Villarty J P. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995; 268: 1347–1349
   PubMed Web of Science ®Google Scholar
• Fisher G H, Rosenberg F J, Straus S E, Dale J K, Middleton L A, Lin A Y, Strober W, Lenardo M J, Puck J M. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995; 81: 935–946
   PubMed Web of Science ®Google Scholar
• Bettinardi A, Brugnoni D, Quiros-Rolden E, Malagoli A, La Grutta S, Correra A, Notarangelo D. Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: A molecular and immunological analysis. Blood 1997; 89: 902–909
   PubMed Web of Science ®Google Scholar
• Robertson M J, Manley T J, Pichert G, Cameron C, Cochran K J, Levine H, Ritz J. Functional consequences of APO-1/Fas (CD95) antigen expression by normal and neoplastic hematopoietic cells. Leuk and Lymph 1995; 17: 51–61
   PubMed Web of Science ®Google Scholar
• Strasser A, Huang D CS, Vaux D L. The role of the bcl-2/ced-9 gene family in cancer and general implications of defects in cell death control for tumourigenesis and resistance to chemotherapy. Biochim Biophys Acta 1997; 1333: F151–F178
   PubMed Web of Science ®Google Scholar
• Hallek M, Bergsagel P L, Anderson K C. Multiple myeloma: Increasing evidence for a multistep transformation process. Blood 1998; 91: 3–21
   PubMed Web of Science ®Google Scholar
• Westendorf J J, Lammert J M, Jelinek D F. Expression and function of Fas (APO-1/CD95) in patient myeloma cells and myeloma cell lines. Blood 1995; 12: 3466–3576
   Google Scholar
• Shima Y, Nishimoto N, Ogata A, Fujii Y, Yoshizaki K, Kishimoto T. Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis. Blood 1995; 3: 757–764
   Google Scholar
• Tu Y, Renner S, Xu F, Fleishman A, Taylor J, Weisz J, Vescio R, Rettig M, Berenson J, Krajewski S, Reed J C, Lichtenstein A. Bcl-X expression in multiple myeloma: Possible indicator of chemoresistance. Cancer Research 1998; 58: 256–262
   PubMed Web of Science ®Google Scholar
• Catlett-Falcone R, Landowski T H, Oshiro M M, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna J L, Nunez G, Dalton W S, Jove R. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10: 105–115
   PubMed Web of Science ®Google Scholar
• Landowski T H, Qu N, Buyuksal I, Painter J S, Dalton W S. Mutations in the Fas antigen of multiple myeloma patients. Blood 1997; 90: 4266–4270
   PubMed Web of Science ®Google Scholar
• Fiucci G, Ruberti G. Detection of polymorphisms within the Fas cDNA gene sequence by GC-clamp denaturing gradient gel electrophoresis. Immunogen 1995; 39: 437–439
   Web of Science ®Google Scholar
• DeVita V.T. Jr, Canellos G.P. The lymphomas. Semin Hematol 1999 Oct; 36 (4 Suppl7):84-94 1999; 36(4):84-94.
   Google Scholar
• Dirks W, Schone S, Uphoff C, Quentmeier H, Pradella S, Drexler H G. Expression and function of CD95 (Fas/APO-1) in leukaemia-lymphoma toumor lines. Br J Haematology 1997; 96: 584–593
   PubMed Web of Science ®Google Scholar
• Xerri L, Devilard E, Hassoun J, Haddad P, Birg F. Malignant and reactive cells from human lymphomas frequently express Fas ligand but display a different sensitivity to Fas-mediated apoptosis. Leukemia 2000; 11(11)1868–1877
   Web of Science ®Google Scholar
• Plumas J, Jacob M-C, Chaperot L, Molens J-P, Sotto J-J, Bensa J-C. Tumor B cells from non-Hodgkin's lymphoma are resistant to CD95 (Fas/APO-1)-mediated apoptosis. Blood 1998; 91: 2875–2885
   PubMed Web of Science ®Google Scholar
• Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Samashima M, Hase A, Seto Y, Nagata S. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66: 233–243
   PubMed Web of Science ®Google Scholar
• Cheng J, Liu C, Koopman W J, Mountz J D. Characterization of human Fas gene: Exon/intron organization and promoter region. J Immunol 1995; 154: 1239–1245
   PubMed Web of Science ®Google Scholar
• Xerri L, Carbuccia N, Parc P, Birg F. Search for rearrangements and/or allelic loss of the fas/APO-1 gene in 101 human lymphomas. Am J Clin Pathol 1995; 104: 424–430
   PubMed Web of Science ®Google Scholar
• Daniel P T, Oettinger U, Mapara M Y, Bommert K, Bargou R, Dorken B. Activation and activation-induced death of human tonsillar B cells and Burkitt lymphoma cells: lack of CD95 (Fas/APO-1) ligand expression and function. Eur J Immunol 1997; 27: 1029–1034
   PubMed Web of Science ®Google Scholar
• Mullauer L, Mosberger I, Chott A. Fas ligand expression in nodal non-Hodgkin's lymphomas. Mod Pathol 1998; 11: 369–375
   PubMed Web of Science ®Google Scholar
• Mandik L, Nguyen K-AT, Erikson J. Fas receptor expression on B-lineage cells. Eur J Immunol 1995; 25: 3148–3154
   PubMed Web of Science ®Google Scholar
• Bertoni F, Conconi A, Luminari S, Realini C, Roggero E, Baldini L, Carobbio S, Cavalli F, Neri A, Zucca E. Lack of CD95/Fas gene somatic mutations in extranodal, nodal and splenic marginal zone B cell lymphomas. Leukemia 2000; 14: 446–448
   PubMed Web of Science ®Google Scholar
• Gronbaek K, Straten P T, Ralfkiaer E, Ahrenkiel V, Andersen M K, Hansen M E, Zeuthen J, Hou-Jensen K, Guldberg P. Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood 1998; 92(9)3018–3024
   PubMed Web of Science ®Google Scholar
• Tamiya S, Etoh K, Suzushima H, Takatsuki K, Matsuoka M. Mutation of CD95 (Fas/Apo-1) gene in adult T-cell leukemia cells. Blood 1998; 91: 3935–3942
   PubMed Web of Science ®Google Scholar
• Beltinger C, Kurz E, Bonier T, Schrappe M, Ludwig W-D, Debatin K-M. CD95 (APO-1/Fas) mutations in childhood T-lineage acute lymhoblastic leukemia. Blood 1998; 91: 3943–3951
   PubMed Web of Science ®Google Scholar
• Eischen C M, Kottke T J, Martins LM, Basi G S, Tung J S, Earnshaw W C, Leibson P J, Kaufmann S H. Comparison of apoptosis in wild-type and Fas-resistant cells: Chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood 1997; 90: 935–943
   PubMed Web of Science ®Google Scholar
• Villunger A, Egle A, Kos M, Hartmann B L, Geley S, Kofler R, Greil R. Drug-induced apoptosis is associated with enhanced Fas (APO-1/CD95) ligand expression but occurs independently of Fas (APO-1/CD95) signaling in human T-acute lymphatic leukemia cells. Cancer Research 1997; 57: 3331–3334
   PubMed Web of Science ®Google Scholar
• Landowski T H, Shain K H, Oshiro M M, Buyuksal I, Painter J S, Dalton W S. Myeloma cells selected for resistance to CD95-mediated apoptosis are not cross-resistant to cytotoxic drugs: Evidence for independent mechanisms of caspase activation. Blood 1999; 94: 265–274
   PubMed Web of Science ®Google Scholar
• Shain K H, Landowski T H, Buyuksal I, Cantor A B, Dalton W S. Clonal variability in CD95 expression is the major determinant in Fas-mediated, but not chemotherapy mediated apoptosis in the RPMI 8226 multiple myeloma cell line. Leukemia 2000; 14: 830–840
   PubMed Web of Science ®Google Scholar
• Lamy T, Loughran TP, Jr. Current concepts: large granular lymphocyte leukemia. Blood Rev 1999; 13(4)230–240
   PubMed Web of Science ®Google Scholar
• Lamy T, Liu J H, Landowski T H, Dalton W S, Loughran TP, Jr. Dysregulation of CD95/CD95 ligand-apoptotic pathway in CD3(+) large granular lymphocyte leukemia. Blood 1998; 92: 4771–4777
   PubMed Web of Science ®Google Scholar
• Liu J H, Wei S, Lamy T, Epling-Burnette P K, Starkebaum G, Djeu J Y, Loughran TP, Jr. Chronic neutropenia mediated by fas ligand. Blood 2000; 95: 3219–3233
   PubMed Web of Science ®Google Scholar
• Cascino I, Fiucci G, Papoff G, Ruberti G. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol 1995; 154: 2706–2713
   PubMed Web of Science ®Google Scholar
• Natoli G, Ianni A, Costanzo A, De Petrillo G II, Chirillo P, Balsano C, Levrero M. Resistance to Fas-mediated apoptosis in human hepatoma cells. Oncogene 1995; 11: 1157–1164
   PubMed Web of Science ®Google Scholar
• Cheng J, Zhou T, Liu C, Shapiro J P, Brauer M J, Kiefer M C, Barr P J, Mountz J D. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1995; 263: 1759–1762
   Web of Science ®Google Scholar
• Inaba H, Komada Y, Li Q-S, Zhang X-L, Tanaka S, Azuma E, Yamamoto H, Sakurai M. mRNA expression of variant Fas molecules in acute Leukemia cells. Am J Hematology 1999; 62: 150–159
   PubMed Web of Science ®Google Scholar
• Muschen M, Warskulat U, Beckmann M W. Defining CD95 as a tumor suppressor gene. J Mol Med 2000; 78: 312–325
   PubMed Web of Science ®Google Scholar
• Landowski T H, Gleason-Guzman M C, Dalton W S. Selection for drug resistance results in resistance to Fas mediated apoptosis. Blood 1997; 89: 1180–1187
   Google Scholar
• Schneider T J, Grillot D AM, Foote L C, Nvmez G E, Rothstein T L. Bel-XL protects primary B cells against Fas-mediated apoptosis. J Immunol 1997; 159: 4834–4839
   PubMed Web of Science ®Google Scholar
• Owen-Schaub L B, Zhang W, Cusack J C, Angelo L S, Santee S M, Fujiwara T, Roth J A, Deisseroth A B, Zhang W-W, Kruzel E, Radinsky R. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol 1995; 15: 3032–3040
   PubMed Web of Science ®Google Scholar
• Fenton R G, Hixon J A, Wright P A, Brooks A D, Sayers T J. Inhibition of Fas (CD95) expression and Fas-mediated apoptosis by oncogenic Ras. Cancer Research 1998; 58: 3391–3400
   PubMed Web of Science ®Google Scholar
• Hughes S J, Nambu Y, Soldes O S, Hamstra D, Rehemtulla A, Iannettoni M D, Orringer M B, Beer D G. Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma. Cancer Research 1997; 57: 5571–5578
   PubMed Web of Science ®Google Scholar
• Bennett M, Macdonald K, Chan S W, Luzio J P, Simari R, Weissberg P. Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science 1998; 282: 290–293
   PubMed Web of Science ®Google Scholar
• Rathmell J C, Townsend S E, Xu J C, Flavell R A, Goodnow C C. Expansion or elimination of B cells in vivo: Dual roles for CD40-and Fas (CD95)-ligands modulated by the B cell antigen receptor. Cell 1996; 87: 319–329
   PubMed Web of Science ®Google Scholar
• Lagresle C, Bella C, Daniel F T, Krammer P H, Defrance T. Regulation of germinal center B cell differentiation: Role of the human APO-1/Fas (CD95) molecule. J Immunol 1995; 154: 5746–5756
   PubMed Web of Science ®Google Scholar
• Garrone P, Neidhardt E-M, Garcia E, Galibert L, van Kooten C, Banchereau J. Fas ligation induces apoptosis of CD40-activated human B lymphocytes. J Exp Med 1995; 182: 1265–1273
   PubMed Web of Science ®Google Scholar
• Wang J, Taniuchi I, Maekawa Y, Howard M, Cooper M D, Watanabe T. Expression and function of Fas antigen on activated murine B cells. Eur J Immunol 1996; 26: 92–96
   PubMed Web of Science ®Google Scholar
• Epling-Burnette PK, Liu J H, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, Li Y, Wang J M, Yang-Yen H F, Karras J, Jove R, Loughran TP, Jr. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest. 2001; 107: 351–362
   PubMed Web of Science ®Google Scholar